NCT07148739PHASE4Recruiting

Ensuring Access to Optimal Therapy in CF: The ENACT Study

Arkansas Children's Hospital Research Institute

Start Date

6/10/2025

Completion Date

12/1/2030

Summary

This clinical trial is examining the action and effects of several new drugs in the treatment of cystic fibrosis in children. In addition, several genetic factors are examined. The hope is that the ability to determine prior to treatment those individuals who will or will not respond to existing therapies will avoid needless risk of side effects and the high cost of a potentially ineffective treatment regimen. Understanding the way these drugs work in the body and the best way to study them is critical to expanding the use of these drugs to all patients with cystic fibrosis (CF).

Detailed Description

Understanding variation in genetic response to pharmacological treatments and personalized CFTR modulator response is crucial to the optimization of the use of these novel compounds; expansion to all patients who might benefit from them; and development of predictive biomarkers. In addition, the ability to determine prior to treatment those individuals who will or will not respond to existing therapies will avoid needless risk of side effects and the high cost of a potentially ineffective treatment regimen. Understanding the way these drugs work in the body and the best way to study them and the downstream effects is critical to expanding the use of these drugs to all patients with cystic fibrosis (CF).

Eligibility Criteria

Age Range: 3 years to No maximum

Inclusion Criteria: * documentation of CF diagnosis per CFF diagnostic criteria and known CFTR genotype * age 2 years and older * ability to provide written informed consent and/or assent (by subject and/or legal guardian) * on a stable dose of triple combination CFTR modulator therapy for at least two weeks prior to Visit 1 * clinically stable lung disease, defined as no documented acute decrease in FEV1 \> 10%, OR use of additional antibiotics (intravenous \[IV\] or oral \[PO\]) within 4 weeks prior to screening Exclusion Criteria: * recent significant unintentional weight loss, as determined by the investigator, in the 4 weeks prior to screening * pregnant or breastfeeding female * history of alcohol or substance abuse in the 6 months prior to screening * participation in a study involving an investigational intervention within 28 days (or 5 half-lives, whichever is longer) prior to screening * in the opinion of the Investigator, medical or psychiatric illness, or other conditions that would interfere with participation

Interventions

DRUG

Elexacaftor / Ivacaftor / Tezacaftor

OTHER

therapeutic drug monitoring

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Cystic Fibrosis (CF)

Locations

The University of Alabama at Birmingham

Birmingham, Alabama 35233

United States

Arkansas Children's Hospital

Little Rock, Arkansas 72205

United States

University of Washington

Seattle, Washington 98195

United States